Literature DB >> 31215096

Can clinical radiomics nomogram based on 3D multiparametric MRI features and clinical characteristics estimate early recurrence of pelvic chondrosarcoma?

Ping Yin1, Ning Mao2, Xia Liu1, Chao Sun1, Sicong Wang3, Lei Chen1, Nan Hong1.   

Abstract

BACKGROUND: Chondrosarcoma (CS) is the second most common primary malignant bone tumor, with a relatively high recurrence rate. However, an effective method that estimates whether pelvic CS will recur after surgery, which influences the formulation of a clinical treatment plan, remains lacking.
PURPOSE: To develop and validate a clinical radiomics nomograms based on 3D multiparametric magnetic resonance imaging (mpMRI) features and clinical characteristics that could estimate early recurrence (ER) (≤1 year) of pelvic CS. STUDY TYPE: Retrospective. POPULATION: In all, 103 patients (ER = 41, non-ER = 62) with histologically proven CS were retrospectively analyzed and divided into a training set (n = 72) and a validation set (n = 31). FIELD STRENGTH/SEQUENCE: 3.0T axial T1 -weighted (T1 -w), T2 -weighted (T2 -w), diffusion weighted imaging (DWI), contrast-enhanced T1 -weighted (CET1 -w). ASSESSMENT: Risk factors (sex, age, type, grade, resection margins, etc.) associated with ER were evaluated. Five individual models based on T1 -w, T2 -w, DWI, CET1 -w, and clinical data were built. Then we compared the performance of models based on T1 -w, T2 -w, CET1 -w and their combination. Lastly, two nomograms based on the best model + clinical data and DWI + clinical data were built. STATISTICAL TESTS: The area under the receiver operating characteristic curve (AUC) and accuracy (ACC) were used to evaluate different models.
RESULTS: Grade was the most important univariate clinical predictor of ER of pelvic CS patients (odds ratio [OR]1 = 4.616, OR2 = 8.939, P < 0.05). T1 -w + T2 -w + CET1 -w had a significantly higher performance than CET1 -w in the training set (P = 0.01). Radiomics features are more important than clinical characteristics in clinical radiomics nomograms, especially for multisequence combined features (OR = 3.208, P < 0.01). Clinical radiomics nomogram based on combined features (T1 -w + T2 -w + CET1 -w) + clinical data achieved an AUC of 0.891 and ACC of 0.857, followed by DWI + clinical data (AUC = 0.882, ACC = 0.760) in the validation set. DATA
CONCLUSION: The clinical radiomics nomogram had good performance in estimating ER of pelvic CS patients, which would be helpful in clinical decision-making. LEVEL OF EVIDENCE: 4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2020;51:435-445.
© 2019 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  chondrosarcoma; magnetic resonance imaging; nomogram; radiomics; recurrence

Mesh:

Year:  2019        PMID: 31215096     DOI: 10.1002/jmri.26834

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  15 in total

1.  Multi-Sequence MR-Based Radiomics Signature for Predicting Early Recurrence in Solitary Hepatocellular Carcinoma ≤5 cm.

Authors:  Leyao Wang; Xiaohong Ma; Bing Feng; Shuang Wang; Meng Liang; Dengfeng Li; Sicong Wang; Xinming Zhao
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

2.  Multiparametric radiomics nomogram may be used for predicting the severity of esophageal varices in cirrhotic patients.

Authors:  Shang Wan; Yi Wei; Xin Zhang; Xijiao Liu; Weiwei Zhang; Yuhao He; Fang Yuan; Shan Yao; Yufeng Yue; Bin Song
Journal:  Ann Transl Med       Date:  2020-03

3.  Radiomics Nomogram of DCE-MRI for the Prediction of Axillary Lymph Node Metastasis in Breast Cancer.

Authors:  Ning Mao; Yi Dai; Fan Lin; Heng Ma; Shaofeng Duan; Haizhu Xie; Wenlei Zhao; Nan Hong
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

4.  CT-Based Radiomics Signatures for Predicting the Risk Categorization of Thymic Epithelial Tumors.

Authors:  Jin Liu; Ping Yin; Sicong Wang; Tao Liu; Chao Sun; Nan Hong
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

5.  Radiomics Models for the Preoperative Prediction of Pelvic and Sacral Tumor Types: A Single-Center Retrospective Study of 795 Cases.

Authors:  Ping Yin; Xin Zhi; Chao Sun; Sicong Wang; Xia Liu; Lei Chen; Nan Hong
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

6.  Clinical-Deep Neural Network and Clinical-Radiomics Nomograms for Predicting the Intraoperative Massive Blood Loss of Pelvic and Sacral Tumors.

Authors:  Ping Yin; Chao Sun; Sicong Wang; Lei Chen; Nan Hong
Journal:  Front Oncol       Date:  2021-10-25       Impact factor: 6.244

Review 7.  Chondrosarcoma-from Molecular Pathology to Novel Therapies.

Authors:  Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

8.  CT and MRI radiomics of bone and soft-tissue sarcomas: a systematic review of reproducibility and validation strategies.

Authors:  Salvatore Gitto; Renato Cuocolo; Domenico Albano; Francesco Morelli; Lorenzo Carlo Pescatori; Carmelo Messina; Massimo Imbriaco; Luca Maria Sconfienza
Journal:  Insights Imaging       Date:  2021-06-02

9.  Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer.

Authors:  Tian-Yu Tang; Xiang Li; Qi Zhang; Cheng-Xiang Guo; Xiao-Zhen Zhang; Meng-Yi Lao; Yi-Nan Shen; Wen-Bo Xiao; Shi-Hong Ying; Ke Sun; Ri-Sheng Yu; Shun-Liang Gao; Ri-Sheng Que; Wei Chen; Da-Bing Huang; Pei-Pei Pang; Xue-Li Bai; Ting-Bo Liang
Journal:  J Magn Reson Imaging       Date:  2019-12-23       Impact factor: 4.813

10.  Machine and Deep Learning Based Radiomics Models for Preoperative Prediction of Benign and Malignant Sacral Tumors.

Authors:  Ping Yin; Ning Mao; Hao Chen; Chao Sun; Sicong Wang; Xia Liu; Nan Hong
Journal:  Front Oncol       Date:  2020-10-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.